DK0493468T3 - Antitumor-præparat bestående af interleukin-2 og histamin, analoger dermed eller H2-receptor- agonister - Google Patents

Antitumor-præparat bestående af interleukin-2 og histamin, analoger dermed eller H2-receptor- agonister

Info

Publication number
DK0493468T3
DK0493468T3 DK90914257.2T DK90914257T DK0493468T3 DK 0493468 T3 DK0493468 T3 DK 0493468T3 DK 90914257 T DK90914257 T DK 90914257T DK 0493468 T3 DK0493468 T3 DK 0493468T3
Authority
DK
Denmark
Prior art keywords
histamine
subject
agent
receptor agonists
receptor
Prior art date
Application number
DK90914257.2T
Other languages
English (en)
Inventor
Jan Kristoffer Hellstrand
Svante Hermodsson
Original Assignee
Syntello Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntello Inc filed Critical Syntello Inc
Application granted granted Critical
Publication of DK0493468T3 publication Critical patent/DK0493468T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK90914257.2T 1989-09-19 1990-09-19 Antitumor-præparat bestående af interleukin-2 og histamin, analoger dermed eller H2-receptor- agonister DK0493468T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40935789A 1989-09-19 1989-09-19

Publications (1)

Publication Number Publication Date
DK0493468T3 true DK0493468T3 (da) 1996-08-26

Family

ID=23620128

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90914257.2T DK0493468T3 (da) 1989-09-19 1990-09-19 Antitumor-præparat bestående af interleukin-2 og histamin, analoger dermed eller H2-receptor- agonister

Country Status (12)

Country Link
US (1) US5348739A (da)
EP (1) EP0493468B1 (da)
JP (1) JP2845622B2 (da)
KR (1) KR100195392B1 (da)
AT (1) ATE136786T1 (da)
AU (1) AU640954B2 (da)
CA (1) CA2066728C (da)
DE (1) DE69026620T2 (da)
DK (1) DK0493468T3 (da)
ES (1) ES2087163T3 (da)
NO (1) NO921050D0 (da)
WO (1) WO1991004037A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107771A0 (en) * 1992-11-27 1994-02-27 Wellcome Found Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation
EP0775197A1 (en) * 1994-08-08 1997-05-28 Maxim Pharmaceuticals, Inc. Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US6071942A (en) 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
AU778012B2 (en) * 1996-05-14 2004-11-11 Maxim Pharmaceuticals, Inc. Administration of histamine for therapeutic purposes
AU9794698A (en) 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
IL141627A0 (en) * 1998-08-24 2002-03-10 Maxim Pharm Inc Activation and protection of t-cells (cd4+and cd8+) using an h2 receptor agonist and other t-cell activating agents
US6498181B1 (en) 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6153113A (en) * 1999-02-22 2000-11-28 Cobe Laboratories, Inc. Method for using ligands in particle separation
CA2377247A1 (en) * 1999-07-16 2001-01-25 Maxim Pharmaceuticals, Inc. Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
US6354986B1 (en) 2000-02-16 2002-03-12 Gambro, Inc. Reverse-flow chamber purging during centrifugal separation
CN1741811A (zh) * 2002-03-29 2006-03-01 马克西姆医药公司 Rom产生与释放抑制剂治疗和预防眼内损伤的用途
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US20060079510A1 (en) * 2004-09-30 2006-04-13 Kristoffer Hellstrand Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis
RU2007135362A (ru) 2005-02-25 2009-03-27 Инотек Фармасьютикалз Корпорейшн (Us) Тетрациклические амино- и карбоксамидосоединения и способ их применения
CN101316592A (zh) 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
MX2009009183A (es) 2007-02-28 2009-09-07 Inotek Pharmaceuticals Corp Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos.
EP2419099A2 (en) * 2009-04-16 2012-02-22 Epicept Corporation Composition and use of n-alpha-methylhistamine
WO2012150707A1 (ja) * 2011-05-02 2012-11-08 国立大学法人熊本大学 幹細胞からインスリン産生細胞への分化誘導を促進する低分子化合物および該化合物を用いた幹細胞からインスリン産生細胞への分化誘導方法
EP3644994A4 (en) * 2017-06-29 2021-04-14 Immune Pharmaceuticals, Inc. PROCEDURES FOR DELAYING AND PREVENTING ACUTE MYELOIC LEUKEME RELEASE
WO2019023344A1 (en) * 2017-07-27 2019-01-31 Immune Pharmaceuticals, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF METASTATIC TUMORS

Also Published As

Publication number Publication date
AU640954B2 (en) 1993-09-09
EP0493468A1 (en) 1992-07-08
DE69026620D1 (de) 1996-05-23
EP0493468B1 (en) 1996-04-17
ATE136786T1 (de) 1996-05-15
AU6419190A (en) 1991-04-18
JPH05504548A (ja) 1993-07-15
CA2066728C (en) 2001-12-25
DE69026620T2 (de) 1996-10-02
WO1991004037A1 (en) 1991-04-04
NO921050L (no) 1992-03-18
CA2066728A1 (en) 1991-03-20
KR100195392B1 (ko) 1999-06-15
KR920703078A (ko) 1992-12-17
US5348739A (en) 1994-09-20
NO921050D0 (no) 1992-03-18
JP2845622B2 (ja) 1999-01-13
ES2087163T3 (es) 1996-07-16

Similar Documents

Publication Publication Date Title
NO921050L (no) Anti-svulst preparat bestaaende av interleukin-2 og histamin, analoger derav eller h2 receptor agonister
Goldstein et al. The role of interferon in cancer therapy: a current perspective
Greiner et al. mRNA expression of leukemia‐associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies
IL69731A (en) Homogeneous human interleukin 2,its preparation and pharmaceutical compositions containing it
Miller Intratumor immunologic heterogeneity
KR930007882A (ko) 세포독성 비시클로[7.3.1]트리데 - 4 - 센 - 2,6디인 화합물 및 그의 제조방법
IL83804A (en) Imidazolylguanidine derivatives, processes for preparing them and pharmaceutical compositions containing them
FR2699176B1 (fr) Nouveaux composés bicycliques de pyrimidine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
Chiodoni et al. Different requirements for α‐galactosylceramide and recombinant IL‐12 antitumor activity in the treatment of C‐26 colon carcinoma hepatic metastases
EP0210753A3 (en) Anti-tumor medicament
NO944214D0 (no) Farmasöytiske preparater for rektal administrering, inneholdende alkylsulfonamider som er HT1-agonister
Choudhury et al. Interferons and interleukins in metastatic renal cell carcinoma
Shimizu et al. Effects of a single injection of anti‐asialo GM1 serum on natural cytotoxicity and the growth of a regressive colonic tumor in syngeneic rats
Baxevanis et al. Induction of lymphokine-activated killer activity in mice by prothymosin α
Alpaugh et al. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon
Maeda et al. Production and characterization of tumor infiltrating lymphocyte clones derived from B16-F10 murine melanoma
Wang et al. Treatment of leukemia with fibroblast-mediated interferon-alpha gene therapy alone or in combination with doxorubicin
Sinkovics A reappraisal of cytotoxic lymphocytes in human tumor immunology
Sato et al. Induction of bone formation in an adenoid cystic carcinoma of the maxillary sinus by adoptive immunotherapy involving intra-arterial injection of lymphokine-activated killer cells and recombinant interleukin-2 in combination with radiotherapy
Blaise et al. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): A pilot study in 19 patients.
Robins Purine nucleoside 3′, 5′-cyclic monophosphates as hormonal modulators of cellular proliferation, metastases and lymphocyte response
Betzler et al. Adjuvant intermittent chemoimmunotherapy for primary breast cancer: a prospective study with immunologic follow-up
Voltchek et al. Comparative study of the cytostatic effects of Oliphen and Ukrain
Kim et al. Effects of interleukin-2 transduction on the human hepatoma cell lines using retroviral vector.
Hokland et al. Effect of recombinant alpha interferon on NK and ADCC function in lung cancer patients: results from a phase II trial